48-Year-Old Man Presents With Diffuse Lymphadenopathy

Poll

A 48-year-old man presents with diffuse lymphadenopathy. After further evaluation, a biopsy is performed. What is your diagnosis?

According to the histopathology image below, what is your diagnosis? - See more at: http://www.oncotherapynetwork.com/image-iq/40-year-old-woman-presents-several-liver-nodules#sthash.BhY8QKnL.dpuf According to the histopathology image below, what is your diagnosis? - See more at: http://www.oncotherapynetwork.com/image-iq/40-year-old-woman-presents-several-liver-nodules#sthash.BhY8QKnL.dpuf

A 48-year-old man presents with diffuse lymphadenopathy. According to the histopathology image below, what is your diagnosis?

 

 

What is your diagnosis?

A. Diffuse large B-cell lymphoma
B. Hodgkin lymphoma
C. Follicular lymphoma
D. Dermatopathic lymphadenopathy
Recent Videos
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 67th Annual ASH Meeting in Orlando.
A new clinical trial aims to offer a novel allogenic CAR T-cell product for patients with lymphoma closer to home.
Modification of REMS programs may help patients travel back to community practices sooner, according to Suman Kambhampati, MD.
Symposiums and regional meetings may expand knowledge of how to adopt novel CAR T-cell therapies and bispecific antibodies, said Suman Kambhampati, MD.
It can cause thrombocytopenia and diarrhea, which are generally manageable and not too big a deal.
More follow-up data will better elucidate the impact of frontline use of hypomethylating agents in patients with myelodysplastic syndromes.
Greater direct access to academic oncologists may help address challenges associated with a lack of CAR T education in the community setting.
Related Content
Novel Microbiome-Based Therapy Safe, Tolerable in GI-aGVHD

Novel Microbiome-Based Therapy Safe, Tolerable in GI-aGVHD

Andrea Eleazar, MHS
December 9th 2025
Article

The primary end point of GI overall response rate was met with MaaT013 for GI-aGVHD.

Experts detailed key advances in myelofibrosis, multiple myeloma, and lymphoma at the Society of Hematologic Oncology 2025 Annual Meeting.

Unraveling Key Blood Cancer Takeaways From the 2025 SOHO Meeting

Francesca Palandri, MD, PhD;Sundar Jagannath, MD;Adam J. Olszewski, MD
September 15th 2025
Podcast

Experts detailed key advances in myelofibrosis, multiple myeloma, and lymphoma at the Society of Hematologic Oncology 2025 Annual Meeting.

Increased Dose of Axatilimab Noted as Tolerable in cGVHD

Increased Dose of Axatilimab Noted as Tolerable in cGVHD

Kristie L. Kahl
December 6th 2025
Article

“Overall, these findings support the safety and feasibility of axatilimab at a dose of 0.6 mg/kg monthly,” said Nosha Farhadfar, MD.

A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.

Navigating AE Management for Cellular Therapy Across Hematologic Cancers

Tiba Al Sagheer, PharmD, BCOP, BCACP;Rebecca Gonzalez, PharmD, BCOP, FASTCT;Syeda Saba Kareem PharmD, BCOP
August 11th 2025
Podcast

A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.

AI revolutionizes palliative oncology by enhancing prognostication, symptom management, and personalized care for patients with hematologic malignancies.

The Role of Artificial Intelligence in Palliative Oncology: Zeroing in on Hematologic Malignancies

Ram Prakash Thirugnanasambandam, MBBS;Ariana Bauer, MD;Christopher D’Angelo, MD
December 3rd 2025
Article

AI revolutionizes palliative oncology by enhancing prognostication, symptom management, and personalized care for patients with hematologic malignancies.

Innate lymphoid cells prevent graft-versus-host disease via IL-9-driven T-cell senescence

Innate lymphoid cells prevent graft-versus-host disease via IL-9-driven T-cell senescence

American Society for Transplantation and Cellular Therapy
November 24th 2025
Article

Researchers have observed that HSC–derived innate lymphoid cells prevent GVHD by inducing interleukin 9 driven T-cell senescence.